Neurological Biomarkers Market Growth, Analysis, Overview and Outlook and Segment to 2020
- Submitted by: Marketreport
- Views: 62
- Category: Other
- Date Submitted: 09/20/2016 03:33 AM
- Pages: 3
- Report this Essay
Technavio Announces the Publication of its Research Report Global Neurological Biomarkers Market 2016-2020
Technavio recognizes the following companies as the key players in the global neurological biomarkers market: Myriad RBM, Proteome Sciences, QIAGEN, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, and Psynova Neurotech.
Browse full report with TOC@ https://marketreportscenter.com/reports/388369/global-neurological-biomarkers-market-2016-2020
Commenting on the report, an analyst from Technavios team said: Integrated biology approach will be the key focus area and a key trend for market growth. Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area.
According to the report, one of the key drivers for market growth will be increasing focus toward drug discovery applications. Close to 1% of medications in the biomarker discovery and development pipeline achieve the commercial success. The rate of failure cases is too high, and very frequently drug candidates fail in the late development phase. This has led to the evolution of alternative biomarker-based techniques by contract research...
Technavio recognizes the following companies as the key players in the global neurological biomarkers market: Myriad RBM, Proteome Sciences, QIAGEN, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, and Psynova Neurotech.
Browse full report with TOC@ https://marketreportscenter.com/reports/388369/global-neurological-biomarkers-market-2016-2020
Commenting on the report, an analyst from Technavios team said: Integrated biology approach will be the key focus area and a key trend for market growth. Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area.
According to the report, one of the key drivers for market growth will be increasing focus toward drug discovery applications. Close to 1% of medications in the biomarker discovery and development pipeline achieve the commercial success. The rate of failure cases is too high, and very frequently drug candidates fail in the late development phase. This has led to the evolution of alternative biomarker-based techniques by contract research...